Peginterferon/Ribavirin Cost Balanced By Increased Efficacy - Schering
Executive Summary
Cost-effectiveness arguments will likely underpin European marketing of Schering-Plough's ViraferonPeg in combination with Rebetol for treatment of chronic hepatitis C, and could be used in U.S. marketing when the combination is approved by FDA.
You may also be interested in...
Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
Roche will study individualized dosing regimens for Pegasys (peginterferon alfa-2a) in combination with ribavirin as part of its postmarketing commitments in Europe
Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
Roche will study individualized dosing regimens for Pegasys (peginterferon alfa-2a) in combination with ribavirin as part of its postmarketing commitments in Europe
Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen
Schering-Plough will study alternative dosing regimens for PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin) following approval of the hepatitis C combination therapy.